Catalog |
name |
Description |
price |
R-R-3012 |
ESI-08 CAS No.301177-43-5 |
ESI-08/CAS No.301177-43-5 is a potent and selective EPAC antagonist, which can completely inhibit both EPAC1 and EPAC2 (IC50 of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced EPAC activation, but does not inhibit cAMP-mediated PKA activation. |
price> |
R-R-3013 |
ASP2453 CAS No.2241719-73-1 |
ASP2453/CAS No.2241719-73-1 is a potent, selective and covalent KRAS G12C inhibitor. ASP2453 inhibits the Son of Sevenless (SOS)-mediated interaction between KRAS G12C and Raf with an IC50 value of 40 nM. |
price> |
R-R-3014 |
Y16 CAS No.429653-73-6 |
Y16/CAS No.429653-73-6 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a Kd value of 76 nM. Y16 is active in blocking the interaction of LARG and related G-protein-coupled Rho GEFs with RhoA. Y16 shows no detectable effect on other diffuse B-cell lymphoma (Dbl) family Rho GEFs, Rho effectors, or a RhoGAP. |
price> |
R-R-3015 |
K-Ras(G12C) inhibitor 12 CAS No.1469337-95-8 |
K-Ras(G12C) inhibitor 12/CAS No.1469337-95-8 is a K-Ras(G12C) inhibitor, the half-maximum effective concentration (EC50) for K-Ras(G12C) inhibitor 12 in H1792 cells is 0. |
price> |
R-R-3016 |
KRas G12R inhibitor 1 |
KRas G12R inhibitor 1 (compound 3) is a KRas G12R selective covalent inhibitor that exploits the strong nucleophilicity of mutant cysteines and binds irreversibly in the Switch II region of K-Ras. KRas G12R inhibitor 1 can be used in cancer research. |
price> |
R-C-1317 |
APD597 (JNJ-38431055) CAS:897732-93-3 |
APD597 is a GPR119 agonist intended for the treatment of type 2 diabetes,with EC50 of 46 nM for hGPR119.IC50 value: 46 nM(EC50)Target:hGPR119The design and synthesis of a second generation GPR119-agonist clinical candidate for the treatment of diabetes is described.APD597 was selected for preclinical development based on a good balance between agonist potency,intrinsic activity and in particular on its good solubility and reduced drug-drug interaction potential. |
price> |
R-R-3017 |
ZT-12-037-01 CAS No.2328073-61-4 |
ZT-12-037-01/CAS No.2328073-61-4 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM. |
price> |
R-R-3018 |
KRAS G12D inhibitor 14 CAS No.2765254-39-3 |
KRAS G12D inhibitor 14/CAS No.2765254-39-3 is a potent KRAS G12D inhibitor with a KD of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D. |
price> |
R-R-3019 |
XRP44X CAS No.729605-21-4 |
XRP44X/CAS No.729605-21-4 inhibits Ras-induced transcription activation with the IC50 of 10 nM. XRP44X inhibits activation of the Ras-Erk-1/2 pathway by FGF-2. XRP44X is an inhibitor of Ras/Erk activation of Elk3 that also affects microtubules. |
price> |
R-R-3020 |
SAH-SOS1A TFA CAS No.2896737-31-6 |
SAH-SOS1A TFA/CAS No.2896737-31-6 is a peptide-based SOS1/KRAS protein interaction inhibitor. SAH-SOS1A TFA binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106-175 nM). SAH-SOS1A TFA directly and independently blocks nucleotide association. SAH-SOS1A TFA impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS. |
price> |